HoldConviction 5.6/10PW target $480.00+10.9%Rated May 29Full research page
Verdict
Intuitive Surgical operates the most durable razor/razorblade model in medical devices: an 11,106-system installed base (incl. 1,231 da Vinci 5) generates 75%+ recurring revenue from instruments, accessories, and services tied to procedure volume growth. The da Vinci 5 upgrade cycle (force feedback, enhanced AI visualization) drives both system ASP uplift and higher utilization per system, while the Ion endoluminal platform (51% procedure growth in FY2025) is an emerging second growth vector. Competition from Medtronic Hugo (FDA-cleared Dec 2025, urology only) and J&J Ottava (FDA submitted Jan 2026) is real but years behind ISRG's ecosystem lock-in — hospitals do not switch robotic platforms lightly given surgeon training, workflow integration, and clinical evidence requirements.
Scenario
Prob.
Target
Driver
Bull
25%
$600.00
da Vinci 5 upgrade cycle accelerates — 2,000+ da Vinci 5 placements in 2026 (vs 1,231 cumulative by end 2025)
Base
50%
$490.00
da Vinci procedure growth 13-15% in 2026, in line with management guidance
Bear
25%
$340.00
Procedure growth decelerates below 12% — da Vinci penetration approaching saturation in US
Change history
May 29View held
FDA Class I recall — SureForm 30 Gray Reloads (manual research-update)
Apr 12View held
Initial deep research and thesis construction
Watching
Medtronic Hugo FDA clearance for urologyDec 3, 2025216d ago
Q4 2025 / FY2025 earnings releaseJan 22166d ago
da Vinci 5 cardiac clearance announcedJan 31157d ago
FY2025 10-K filingFeb 3154d ago
European distributor acquisition completed (Italy, Spain, Portugal)Mar 1128d ago
Q1 2026 earnings releaseApr 2177d ago
Q1 2026 earnings — first full quarter with cardiac clearance impact and international da Vinci 5 dataApr 2177d ago
da Vinci 5 cardiac adoption — validates new specialty TAM expansion thesisApr 2177d ago
Ion installed base growth toward 1,500 systems — validates second growth vectorApr 2177d ago
Medtronic Hugo general surgery/gynecology FDA clearance pursuit — expands competitive footprintJun 307d ago
Q2 2026 earnings release (estimated)Jul 22in 15d
da Vinci 5 international rollout expansion — CE mark achieved, tracking multi-country launchJul 22in 15d
SureForm 30 Gray Reloads Class I recall resolution — FDA-terminated status with no inspection escalation; gauge any I&A revenue / reliability-narrative spillover at Q2 earningsJul 22in 15d
J&J Ottava FDA clearance decision — creates second major US competitor if approvedSep 30in 85d
Q3 2026 earnings release (estimated)Oct 21in 106d
Medtronic Hugo general surgery FDA clearance pursuit (timeline TBD)Dec 31in 177d
Worldwide da Vinci procedure growth decelerates below 12% for two consecutive quarters — US penetration saturation
Medtronic Hugo receives FDA general surgery + gynecology clearances AND 3+ major hospital systems adopt dual-vendor robotic strategy
J&J Ottava clears FDA and launches aggressive Ethicon bundling — leverages existing surgical instrument franchise for penetration pricing
Operating margin compresses below 27% for two consecutive quarters — competitive pricing pressure or tariff escalation
China pricing restrictions expand nationally; da Vinci procedure volumes in China decline >20% YoY
Instruments and accessories revenue per procedure declines >5% YoY — pricing pressure from competition or regulatory
SureForm Class I recall escalates — FDA inspection finding (Form 483 / warning letter) on instruments quality systems OR recall scope expands beyond the 8mm gray reload SKU
da Vinci 5 system placements exceed 800 units in Q1 2026 — upgrade cycle accelerating beyond expectations
Cardiac procedure adoption exceeds 10,000 da Vinci cardiac cases in first 12 months post-clearance
Ion installed base crosses 1,500 systems and procedure growth sustains above 40% — lung biopsy becoming material revenue contributor
Hugo/Ottava commercial launches underwhelm — utilization rates <50% of da Vinci at comparable hospital sites
International revenue growth exceeds 25% YoY for 2+ consecutive quarters — OUS penetration inflecting
da Vinci 5 AI guidance features (Case Insights, Force Gauge) demonstrate measurably superior surgical outcomes in clinical studies
Latest notes
May 29Update — FDA Class I recall on SureForm 30 Gray Reloads + da Vinci X/Xi screw recalls